Novo Nordisk A/s

This study tested whether semaglutide, a medication used for diabetes and weight loss, could help reduce inflammation in the brains of people with Alzheimer's disease. For 12 weeks, 23 participants with mild Alzheimer's symptoms received either the real medication or a placebo in…

This study tested whether a new weekly injection called CagriSema could help people with type 2 diabetes better control their blood sugar and lose weight. The medicine was given to about 274 adults who were already taking daily insulin, with or without metformin, for one year. Re…

This study tested whether a monthly injection called Ziltivekimab could reduce harmful inflammation in people with advanced chronic kidney disease. 264 participants with kidney disease and signs of high inflammation received either the drug at different doses or a placebo shot fo…

This study tested whether a new weekly injection called CagriSema helps people with excess body weight lose more weight than an existing medicine, semaglutide. It involved 331 East Asian adults with overweight or obesity, some of whom also had type 2 diabetes. Participants receiv…

This study tested different ways to gradually increase the dose of an experimental weight management medication called NNC0519-0130. Researchers wanted to see if certain dosing methods could reduce side effects that sometimes occur when starting new medications. The 24-week trial…

This study tested whether a new once-weekly injection called IcoSema works as well as standard daily insulin injections for controlling blood sugar in adults with type 2 diabetes. 679 participants either received the weekly injection or daily insulin injections for about one year…

This study tested whether a higher-dose daily pill called oral semaglutide could help people with overweight or obesity lose weight. For 68 weeks, 667 participants were randomly assigned to take either the active pill or a placebo (a dummy pill), alongside advice on diet and exer…

This study tested whether a new daily tablet called semaglutide could help Chinese adults with overweight or obesity lose weight. For about a year, 200 participants took either the real medicine or a placebo pill, while also receiving counseling on healthy eating and physical act…

This study tested different doses of a new medicine called NNC0487-0111 to see if it could help people with type 2 diabetes lower their blood sugar and lose weight. 448 participants received either the new medicine (as a weekly injection or daily pill) or a placebo for about 43 w…

This study monitored 300 obese adults and adolescents in Taiwan who were already prescribed Saxenda, a weight management medication. Researchers tracked the drug's safety and how well it helped patients lose weight during 26 weeks of normal clinical use. The goal was to understan…

This study observed 336 UK adults with type 2 diabetes who were prescribed the once-daily pill Rybelsus (oral semaglutide) by their doctors. Researchers tracked how well the medication worked in everyday life over 8-10 months, focusing on blood sugar control and weight changes. T…

This study tested whether a new weekly injection called semaglutide could help people with overweight or obesity lose weight. About 375 adults either received the real injection or a placebo (dummy medicine) for about a year, along with advice on diet and exercise. The main goal …

This early-stage study tested a new weekly injection called NNC0519-0130 in adults with obesity or type 2 diabetes. Researchers wanted to see if it was safe, how it worked in the body, and if it could help with weight loss and blood sugar control. Participants were randomly assig…

This early-stage study tested whether a potential new medicine for sickle cell disease, called etavopivat, affects the heart's electrical activity. Researchers gave the drug at different doses to 33 healthy volunteers to check for safety, particularly looking at heart rhythm. The…

This study observed how well a smart insulin pen helps adults with type 1 diabetes manage their condition in everyday life. Over 400 participants used the pen, which automatically logs insulin doses and syncs the data with a phone app alongside their continuous glucose monitor re…

This study tested how the drug ziltivekimab works in the body of Chinese adults who have chronic kidney disease and signs of body-wide inflammation. Twenty-four participants received either the drug or a placebo dummy injection three times over several months. Researchers measure…

This study observed how the oral medication Rybelsus (semaglutide) works for people with type 2 diabetes in everyday life. Researchers followed 50 adults in Finland for 8-10 months to see how well the drug controlled their blood sugar and affected their weight. The goal was to co…

This study observed how the oral medication Rybelsus (semaglutide) works for adults with type 2 diabetes in everyday Mexican clinics. Researchers tracked 187 participants for 8-10 months to see how the drug affected blood sugar levels and body weight. The goal was to collect real…

This study monitored the safety and effectiveness of Xultophy, a combination diabetes medication, in routine medical practice. Researchers followed 750 adults with type 2 diabetes in Korea for about 6 months after their doctors prescribed Xultophy. The goal was to see how well th…

This study tested a new investigational medicine called CagriSema, which combines two drugs, to see how it affects the body's insulin sensitivity in people with type 2 diabetes. 158 adults with type 2 diabetes who were already taking metformin received either CagriSema, one of it…

This study observed how well the combination diabetes medication Xultophy worked for 244 Japanese adults with type 2 diabetes in real-world doctor's offices. Participants received Xultophy as prescribed by their doctor, and researchers tracked their blood sugar control and treatm…

This study tested if a new weekly growth hormone medicine (somapacitan) works as well and is as safe as a standard daily medicine (Norditropin®) for children with growth hormone deficiency. 110 Chinese children participated and were randomly assigned to receive either the daily o…

This study tested Mim8, a new medication designed to prevent bleeding episodes in people with hemophilia A, including those with or without inhibitors. Participants received Mim8 injections either once a week or once a month and were compared to their previous treatments. The goa…

This study observed how well the once-daily oral medication Rybelsus (semaglutide) worked for managing type 2 diabetes in everyday life in Saudi Arabia. It involved 194 adults who were prescribed the medication by their doctor as part of their normal care. Researchers tracked cha…

This study observed adults with type 2 diabetes in Italy whose blood sugar was still too high on their current medication. Doctors switched them to a newer pill called oral semaglutide as part of their normal care. Researchers tracked changes in blood sugar, weight, and how patie…

This study tested whether the type 2 diabetes medication semaglutide, taken as a daily pill, could reduce the risk of major heart problems like heart attacks and strokes. Over 9,600 participants with type 2 diabetes and existing heart or kidney disease were randomly assigned to t…

This study tested whether a new, easier-to-use pen injector delivers the same amount of the haemophilia A treatment Mim8 into the blood as a traditional syringe. It involved 205 healthy men who received one injection under the skin. The goal is to make treatment administration si…

This study tested whether a new, once-weekly insulin injection (icodec) could effectively control blood sugar in adults with type 2 diabetes when its dose was adjusted using data from a continuous glucose monitor worn on the arm. Participants, who had not used insulin before, wor…

This study tested whether a new weekly injection called NNC0519-0130 could help people with type 2 diabetes better control their blood sugar and lose weight. About 300 participants received different doses of the injection or a comparison treatment for 40 weeks. Researchers measu…

This study observed how well the once-daily pill Rybelsus (oral semaglutide) works for managing type 2 diabetes in everyday medical practice in Japan. It followed 650 adults for 8-10 months to see how the medication affected their blood sugar levels and body weight, while also tr…

This study tested whether a weekly injection of the medicine semaglutide could improve daily life and reduce body weight for people living with a specific type of heart failure and type 2 diabetes. Over 600 participants were randomly assigned to receive either the real medicine o…

This study tested whether adding a new experimental medicine (NNC0480-0389) to an existing diabetes drug (semaglutide) works better than either drug alone. 500 adults with type 2 diabetes received weekly injections of different drug combinations for about 41 weeks to find the mos…

This study tested whether a weekly injection called semaglutide could help teenagers with overweight or obesity manage their weight. Over 200 teens received either the real medication or a placebo (dummy shot) for about 15 months, along with counseling on healthy eating and activ…

This study tested whether adding a new investigational medicine (NNC0165-1875) to an existing weight management drug (semaglutide) could help people with obesity lose more weight. About 120 adults received either the two-drug combination or semaglutide with a placebo for 26 weeks…

This study tested a new, faster-acting insulin (faster aspart) against a standard insulin (NovoRapid®) in adults with type 1 or type 2 diabetes. Over 300 participants took four daily injections of one of the insulins, combined with a long-acting insulin, for about 7 months. The m…

This study investigated whether a new combination medicine called CagriSema affects how much people eat, their appetite, and how quickly their stomach empties. The 32-week trial involved 62 adults with overweight or obesity, who were randomly assigned to receive either the active…

This study aimed to understand how the diabetes medication semaglutide might help protect the kidneys in people who have both type 2 diabetes and chronic kidney disease. Over one year, 106 participants received either semaglutide or a placebo injection weekly. Researchers used de…

This study tested the safety and effects of weekly semaglutide injections in 104 Chilean adults with type 2 diabetes over 24 weeks. Participants received injections and were monitored for side effects, blood sugar control, and weight changes. The goal was to understand how well t…

This study tested a new long-acting insulin (icodec) that is injected just once a week against a standard daily insulin (degludec) in adults with type 1 diabetes. The goal was to see if the weekly insulin could control blood sugar levels just as effectively and safely over 26 wee…

This study tested a new medication called Mim8, given as a weekly or monthly injection under the skin, to prevent bleeding episodes in people with severe hemophilia A. It involved 275 male participants, including those with and without inhibitors to standard treatments. The main …

This trial tested a new, long-acting version of a missing clotting protein (Factor IX) in young boys with severe hemophilia B who had little to no prior treatment. The goal was to see if regular injections could safely prevent bleeding episodes and effectively treat bleeds when t…

This study tested whether a new weekly growth hormone injection (somapacitan) works as well and is as safe as the standard daily injection (Norditropin®) for children with growth hormone deficiency. Over 200 children participated in this 4-year trial, where they were randomly ass…

This study tested a new once-weekly combination injection called IcoSema against a new once-weekly insulin (icodec) in people whose type 2 diabetes was not well controlled with daily insulin shots. Over 1,200 participants were randomly assigned to receive one of the two injection…

This was the first study in humans for a new medicine called NNC0519-0130. Researchers tested its safety and how the body processes it. They also looked for early signs it could help lower blood sugar and body weight in people with type 2 diabetes or who are overweight. The medic…

This study tested whether a new oral medicine called semaglutide helps children and teenagers better manage their type 2 diabetes when added to their current treatment. For about 15 months, 132 young people aged 10-17 either took semaglutide or a placebo pill, alongside their usu…

This study monitored over 3,000 Japanese patients with type 2 diabetes for about 3 years after their doctor prescribed them Ozempic (semaglutide). The goal was to track the long-term safety of the medication and see how well it controlled blood sugar and weight in everyday use. R…

This study tested whether a daily pill called oral semaglutide could help adults with overweight or obesity lose weight. Over 300 participants took either the real pill or a placebo (a dummy pill) for 64 weeks. Researchers measured how much weight people lost and whether it impro…

This study tested how well a medicine called N8-GP works for preventing and treating bleeding episodes in Chinese patients with severe hemophilia A. Thirty-six male patients aged 12+ who had previously used other hemophilia treatments received N8-GP injections for 7-8 months. Res…

This study tested whether a weekly injection of semaglutide, a medication for weight loss, could improve daily life for people with a specific type of heart failure linked to obesity. Over 500 participants with obesity and heart failure were randomly assigned to receive either th…

This study monitored the safety and effectiveness of Refixia, a treatment for Hemophilia B, during routine medical care in Japan. Researchers followed 28 patients who were already prescribed Refixia by their doctors to track side effects and see how well the treatment controlled …

This study tested a new weekly injection called CagriSema against an existing drug, tirzepatide, to see which helps people with obesity lose more weight. About 800 adults without diabetes received weekly injections for over a year. The main goal was to see if the new combination …

This study tested whether a new medicine called NNC6019-0001 could help people with a specific heart condition where abnormal proteins build up in the heart muscle. About 105 adults with moderate heart symptoms received either the experimental medicine or a placebo through monthl…

This study tested whether a weekly injection called semaglutide helps adults with overweight or obesity lose weight. About 240 participants were randomly assigned to receive either the real medication or a placebo (dummy injection) for one year. Researchers measured how much weig…

This study observed how the diabetes medication Rybelsus (oral semaglutide) works for people with type 2 diabetes in everyday medical practice. Researchers followed 155 adults in Israel for 8-10 months to see how the once-daily pill affected their blood sugar levels and body weig…

This study compared the diabetes pill RYBELSUS® (oral semaglutide) to other common diabetes pills in real-world medical settings. It involved 1,020 adults with type 2 diabetes whose blood sugar wasn't well controlled on metformin alone. Participants were randomly assigned to rece…

This study tested if a new insulin taken just once a week works as well and is as safe as a standard insulin taken once daily. It involved nearly 1,000 adults with type 2 diabetes who were not yet using insulin. The goal was to see if the weekly option could control blood sugar l…

This study tested a new, higher weekly dose (7.2 mg) of the injectable medication semaglutide to see if it helps people with obesity and type 2 diabetes lose more weight and better control their blood sugar than a lower dose or a placebo. Over 500 adults participated for about 1.…

This study tested a new, once-weekly growth hormone injection (NNC0195-0092) to see if it works as well and is as safe as the standard daily injection (Norditropin) for children who need treatment. It involved 76 children, aged 2 to 10, who had never received growth hormone thera…

This study observed how well the daily pill Rybelsus (oral semaglutide) worked for adults with type 2 diabetes in real-world Spanish clinics. Researchers tracked 465 patients for 8-10 months to see changes in blood sugar levels, body weight, and how satisfied people were with the…

This study tested whether a new, higher dose of the medication semaglutide (7.2 mg) is more effective for weight loss than a placebo or a standard lower dose. Over 1,400 adults with obesity received weekly injections alongside lifestyle counseling for 72 weeks. The main goal was …

This study tested if a new insulin, injected just once a week, works as well and is as safe as a standard daily insulin for people with type 2 diabetes. Over 580 participants, who were already using multiple daily insulin injections, were randomly assigned to receive either the w…

This study tested the safety of a new weight control injection called NNC0487-0111 in Chinese men with overweight or obesity. For about 53 days, 36 participants received either the real injection or a placebo (dummy shot) to see how their bodies reacted. The main goal was to chec…

This study observed how well a mobile app called 'Dose Check' helped people with type 2 diabetes manage their insulin (Tresiba) in everyday life. About 179 participants in Saudi Arabia used the app for 6-7 months to get support with their correct insulin dose. The main goal was t…

This study observed how the diabetes medication Rybelsus (oral semaglutide) works for adults with type 2 diabetes in everyday medical practice. Researchers followed 145 patients in the Netherlands for 8-10 months to see how the treatment affected their blood sugar levels and body…

This study tested a new weekly injection called CagriSema to see if it helps people with obesity and type 2 diabetes lose weight and better control their blood sugar. About 1,200 participants were randomly assigned to receive either the real medicine or a placebo (dummy medicine)…

This study checked if it was safe for people with hemophilia A to switch from their current preventive medicine, emicizumab, to a new one called Mim8. It involved 61 adults and adolescents who had been on emicizumab. Participants received Mim8 via a pen injector weekly, every two…

This early-stage study tested two different versions of an experimental medicine called NNC0519-0130, intended for people with excess body weight. Researchers compared how much of each drug formula ended up in the blood of 46 adults with overweight or obesity to see if they were …

This study tested a new, fast-acting insulin designed for use in insulin pumps by people with type 1 diabetes. Researchers compared how quickly and effectively this new insulin (NNC0471-0119) lowers blood sugar compared to a commonly used insulin (aspart). The study involved 43 a…

This study tested whether a new weekly injection called CagriSema could slow kidney damage in adults with type 2 diabetes, chronic kidney disease, and overweight or obesity. It compared CagriSema against its individual components (semaglutide and cagrilintide) and a placebo over …

This study tested if a diabetes medicine (semaglutide) made with a new manufacturing process works the same as the currently available version. About 388 adults with type 2 diabetes received weekly injections of one version or the other for 28 weeks. Researchers primarily checked…

This study tested how a new weight-loss medicine called CagriSema affects people's appetite, food cravings, and brain activity. It involved 164 adults with overweight or obesity, comparing those who received the medicine to those who received a dummy treatment. Researchers used q…

This study tested a medication called N8-GP in young children with severe hemophilia A who had never received treatment. The goal was to see if it was safe and effective at preventing bleeding episodes and stopping bleeds when they occurred. Researchers followed 124 boys under ag…

This study tested whether a weekly injection called semaglutide could help people with obesity and prediabetes lose weight and return their blood sugar to normal levels. Over 200 participants received either the real medicine or a placebo dummy injection for one year, alongside l…

This study tested a new weekly injection called NNC0519-0130 to help people with overweight or obesity lose weight. It involved 355 adults and compared up to six different doses over about 10 months. The main goal was to see how safe the medicine was and how much weight people lo…

This study looked back at medical records of 209 Thai adults with type 2 diabetes to see how well the oral medication semaglutide worked in everyday clinical practice. Researchers checked if the drug helped control blood sugar levels and body weight over 6 to 12 months of treatme…

This study tested whether a new insulin taken just once a week works as well as standard daily insulin for controlling blood sugar in adults with type 2 diabetes. 429 participants who were already using daily insulin were randomly assigned to either switch to the weekly injection…

This study compared the effectiveness of the weight loss medication semaglutide (Wegovy) against four other approved drugs for obesity. It involved 500 employed adults with obesity from diverse job backgrounds across three US companies. The main goal was to see which medication h…

This large, completed study tested a new weekly medicine called CagriSema, which combines two drugs, for people with type 2 diabetes. It aimed to see if the combination works better than either drug alone or a placebo at lowering blood sugar and body weight. Over 2,700 adults who…

This study tested whether adding a weekly injection called semaglutide could allow people with type 2 diabetes to use less daily insulin while still controlling their blood sugar. Researchers compared two approaches over 11 months in 568 overweight adults: one group received the …

This study tested the safety of a new injectable medication called NNC0662-0419 for people with overweight or obesity. It was the first time this experimental drug was given to humans. Researchers monitored 100 participants for about 9 months to see how their bodies handled the m…

This study observed 458 Italian adults with type 2 diabetes who were prescribed the once-daily pill Rybelsus (oral semaglutide) by their doctor. Researchers tracked their blood sugar control and weight changes over 8-10 months to see how the medication works in everyday practice.…

This study followed 194 adults with type 2 diabetes in Canada who were prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked how well the medication controlled blood sugar and affected weight over 8-10 months in everyday medical practice. The study aimed to…

This study observed 99 adults with type 2 diabetes in Denmark who were prescribed the once-daily pill Rybelsus® (oral semaglutide) by their doctor. The goal was to see how well the medication worked in everyday life to lower blood sugar and body weight over 8-10 months. Researche…

This study tested if giving two weekly injectable medicines, cagrilintide and semaglutide, together works better for controlling type 2 diabetes than either medicine alone. About 92 adults with type 2 diabetes participated for about 9 months. The main goal was to see if the combi…

This study tested whether a smartphone app and a small device attached to an Ozempic pen could help people with type 2 diabetes continue their weekly injection treatment. About 300 participants who were already prescribed Ozempic were involved. The goal was to see if this digital…

This trial tested a new, long-acting medication (N9-GP) to control bleeding in children with severe hemophilia B. It involved 25 boys under 13 who had previously used other treatments. The main goals were to see if the drug was safe, how well it prevented and treated bleeds, and …

This study tested a new oral medicine called NDec to see if it could help adults with sickle cell disease. The goal was to see if taking NDec capsules twice a week for about a year could improve blood health and reduce painful crises. Participants were randomly assigned to receiv…

This study tested several new drug combinations to see if they could reduce liver scarring and alcohol use in people with alcohol-related liver disease. About 270 adults with a history of heavy drinking and early signs of liver damage received either the experimental drugs or a p…

This study tested whether giving two weight management medications together in one injection works as well as giving them as two separate injections. It involved 40 adults with overweight or obesity who received weekly injections for 22 weeks. Researchers measured how the body pr…

This study tested a new weekly injection called CagriSema to see if it helps people with overweight or obesity lose weight. It involved 300 Chinese adults and compared CagriSema against a dummy injection and a similar existing medicine (semaglutide) over about one year. The main …

This study tested whether combining a new liver-targeted medicine with an existing diabetes/weight-loss drug could better treat NASH, a serious form of fatty liver disease that causes scarring. About 700 adults with confirmed NASH and liver scarring received weekly injections of …

This study tested a new injectable drug called NNC0487-0111 to see if it is safe and helps with weight loss in people with overweight or obesity. It involved 125 adults who received either the drug or a placebo (dummy) injection. The main goals were to check for side effects and …

This large, completed study tested if higher doses (25 mg and 50 mg) of a once-daily diabetes pill called semaglutide work better than the standard 14 mg dose. Over 1,600 adults with type 2 diabetes took one of the three doses daily for 68 weeks. The main goal was to see which do…

This completed Phase 3 trial tested a new weekly injection called CagriSema in adults with type 2 diabetes whose blood sugar wasn't well controlled by diet and exercise alone. The study compared two doses of CagriSema against a placebo (dummy medicine) in 189 participants over ab…

This large, completed study looked back at health records of over 285,000 overweight or obese adults to see if taking the weekly medication semaglutide was linked to fewer serious heart problems. It focused on three groups: people with existing heart failure, people with heart ar…

This study tested whether a new once-weekly insulin injection works as well as standard daily insulin injections for controlling blood sugar in people with type 2 diabetes. Over 1,000 participants who were not yet using insulin were randomly assigned to receive either the weekly …

This study tested a new preventative medicine called Mim8 in children aged 1-11 with haemophilia A. Mim8 is given as a shot under the skin to try to prevent bleeding episodes. The trial compared Mim8 to other standard treatments to see if it was safe, effective, and easier for fa…

This study tested whether a weekly injection of semaglutide could help Asian adults with obesity lose weight. For about a year, 150 participants either received the active drug or a placebo (dummy) injection, combined with lifestyle counseling. The main goal was to see how much b…

This study tested how well a long-acting medicine called nonacog beta pegol works to prevent and treat bleeding episodes in Chinese men and boys with hemophilia B. Thirty participants received the medicine by injection for about a year to see how well it controlled bleeds and how…

This study tested whether a new once-weekly medicine called IcoSema works as well as daily insulin injections for controlling blood sugar in people with type 2 diabetes. 485 adults whose diabetes wasn't well-controlled with pills participated in this 11-month trial. Researchers r…

This study followed 194 adults with type 2 diabetes in Sweden who were prescribed the once-daily pill Rybelsus (oral semaglutide) by their doctors. The goal was to see how well the medication worked in everyday life to lower blood sugar levels and affect body weight over 8-10 mon…

This study tested if a new insulin, injected just once a week, works as well and is as safe as a standard insulin that is injected once daily. Over 500 adults with type 2 diabetes who were already using insulin participated. The main goal was to see if the weekly insulin controll…

This study tested three different doses of a weekly injection called semaglutide in people with type 2 diabetes who were also overweight. The main goal was to see how well each dose controlled blood sugar levels and helped with weight loss over 40 weeks. Participants, who were al…

This study tested whether a new emergency medication called dasiglucagon works as well as the standard glucagon treatment for quickly raising dangerously low blood sugar in people with type 1 diabetes. The trial involved 38 Asian adults and Japanese adolescents who received both …

This study tested whether a weekly weight loss injection (semaglutide) could also reduce pain and improve daily life for people with obesity and knee osteoarthritis. Over 400 adults received either the real injection or a placebo (dummy medicine) for about 1.5 years, alongside ad…

This study tested whether a weekly injectable diabetes medicine called semaglutide could help people with type 2 diabetes and leg artery disease walk farther with less pain. Nearly 800 participants were randomly assigned to receive either semaglutide or a placebo injection for ab…

This study aimed to understand how eating a high-fat meal affects how the body absorbs a single dose of the experimental drug etavopivat. Sixteen healthy adults took the drug once after fasting and once after a meal, with their blood levels carefully measured. The goal was to gat…

This study analyzed existing national health survey data from over 550,000 Chinese adults to understand how being overweight or obese affects heart disease rates and risk of death. Participants did not receive any treatment; researchers examined their health records and survey an…

This early study tested a new drug being developed for fatty liver disease. Researchers gave a single injection to 33 people, some with liver problems and some with healthy livers, to see how their bodies processed the drug and to check for side effects. The main goal was to unde…

This early study tested a single dose of a new, unapproved medicine called NNC0650-0013, which is being developed to potentially treat type 2 diabetes. The main goal was to check if the medicine is safe and to see how the body processes it. The study involved 11 healthy male volu…

This study tested whether a new drug being developed for sickle cell disease and thalassemia, called etavopivat, changes how the body processes five other common medications. Healthy adult volunteers took etavopivat along with single doses of digoxin, rosuvastatin, midazolam, pit…

This study tested a new tablet version of the medicine semaglutide in healthy volunteers. The main goal was to measure how much of the drug gets into the blood from the new tablet and compare it to an older tablet version. About 260 healthy participants took different doses of th…

This early-stage study tested the safety of a single injection of a new experimental drug called NNC0581-0001. It involved 48 healthy adults and people with a fatty liver condition (hepatic steatosis) to see how their bodies reacted to the medicine. The main goal was to check for…

This study aimed to understand how a new weight management drug, cagrilintide, is processed by the body. Researchers compared how people with different levels of liver function absorbed and cleared the drug after a single injection. The study also measured how the drug entered th…

This early-stage study tested two different pill versions of an experimental drug combination for sickle cell disease. The goal was to see how the body absorbs a tablet versus a capsule. The study involved 44 healthy volunteers who took both versions in a random order to compare …

This study follows 3,439 people for up to 10 years after they completed a weight-loss medication trial. Participants fill out health questionnaires every 6 months to track long-term outcomes like weight changes, heart health, diabetes risk, and quality of life. No medication or t…

This early-stage study tested a single dose of an experimental weight management medicine called NNC0662-0419. Researchers enrolled 100 Japanese, Chinese, and non-Asian adults with overweight or obesity to measure how much medicine appeared in their blood and check for side effec…

This study looked at existing medical records to understand how common and costly health problems linked to obesity are in Gulf countries. Researchers analyzed data from over 1,300 adults with obesity to see how many had conditions like diabetes, high blood pressure, and heart di…

This early-stage study looked at how a single dose of an experimental drug called etavopivat is processed by the body in people with different levels of liver function. It involved 48 adults, some with stable liver disease and some with healthy livers, to compare drug levels and …

This study aimed to understand how common heart disease is among people with obesity in Saudi Arabia. Researchers collected health information and lifestyle questionnaires from over 1,000 adults during their regular doctor visits. The goal was to gather data to estimate the preva…

This study aimed to understand how common weight-related health problems are among people of different weights in India, Pakistan, the Philippines, and Vietnam. It involved over 1,100 adults who already had at least one weight-related health issue. The research only collected hea…

This study aimed to understand how the body absorbs four different tablet versions of the medication semaglutide, which is used to treat type 2 diabetes. It involved 90 healthy male volunteers and lasted about 28 weeks. The main goal was to compare how much of the drug gets into …

This early-stage study tested the safety and how the body processes a single dose of an experimental obesity medication called monlunabant. It involved 73 healthy, normal-weight Japanese and Caucasian men to see if the drug was well-tolerated and to measure its levels in the bloo…

This study surveyed 1500 heart and kidney doctors in China. The goal was to understand their awareness and views on the role of body-wide inflammation in patients who have both heart and kidney disease. The survey asked about how doctors identify and manage this inflammation in t…

This study aimed to find out how many people in the Middle East with heart disease, with or without kidney disease, have high levels of body-wide inflammation. Researchers collected medical information from 756 participants during a single clinic visit. The study did not test any…

This early study tested a new medicine called etavopivat, which is being developed for sickle cell disease and thalassemia. It involved 24 healthy Chinese volunteers to see how their bodies process a single dose of the drug and to check for any side effects. The main goal was to …

This study tested a new tablet version of the diabetes medicine semaglutide (Rybelsus®) in 121 healthy men. The goal was to see how the amount of water taken with the pill and the timing of breakfast afterward affect how much medicine gets into the bloodstream. Participants took …

This study tested how the body absorbs an experimental medicine called ziltivekimab when given through different injection methods. Researchers compared a regular syringe with a pen-injector (similar to insulin pens) in 267 healthy volunteers. The goal was to understand how quick…

This study was a survey to understand how much doctors, patients, and at-risk people know about a liver condition called MASH and its links to heart and kidney problems. Over 1,300 participants from five countries completed a 25-minute online questionnaire. The study did not test…

This study was a survey of 608 heart and kidney specialists. Its purpose was to understand how these doctors think about and use a specific blood test (hsCRP) to detect hidden inflammation in patients with combined heart and kidney diseases. The goal was to gather real-world info…

This study measured how quickly a new, faster-acting insulin gets into the bloodstream compared to a standard insulin. It involved 23 Chinese adults with type 1 or type 2 diabetes. Each participant received one injection of each insulin type, and researchers took frequent blood s…

This was the first study to give a new drug called NNC0113-6856 to people. The main goal was to check its safety and see how the body absorbs and processes it. The study involved 70 healthy male volunteers who received either a single oral dose or an injection. Researchers measur…

This was the first study in humans to test the safety and body's response to a new, experimental drug called NNC0582-0001. It involved 56 healthy adults who received a single injection under the skin, with some receiving the drug and others receiving a placebo. The main goal was …

This was the first study in humans to test the safety of a new oral medicine called NNC0705-0001. The medicine is being developed to treat chronic inflammation, which increases the risk of heart and kidney disease. The study involved 116 healthy adults to see how safe the drug is…

This early-stage study aimed to see if an experimental drug for type 2 diabetes changes how the body processes a common birth control pill. Researchers also checked if the drug affects how quickly the stomach empties. The study involved 47 healthy postmenopausal women who took th…